278 related articles for article (PubMed ID: 19883630)
1. Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1.
Liang Z; Wu H; Xia J; Li Y; Zhang Y; Huang K; Wagar N; Yoon Y; Cho HT; Scala S; Shim H
Biochem Pharmacol; 2010 Mar; 79(6):817-24. PubMed ID: 19883630
[TBL] [Abstract][Full Text] [Related]
2. miR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2.
Xu K; Liang X; Shen K; Cui D; Zheng Y; Xu J; Fan Z; Qiu Y; Li Q; Ni L; Liu J
Biochem J; 2012 Sep; 446(2):291-300. PubMed ID: 22676135
[TBL] [Abstract][Full Text] [Related]
3. Linc00518 Contributes to Multidrug Resistance Through Regulating the MiR-199a/MRP1 Axis in Breast Cancer.
Chang L; Hu Z; Zhou Z; Zhang H
Cell Physiol Biochem; 2018; 48(1):16-28. PubMed ID: 30001527
[TBL] [Abstract][Full Text] [Related]
4. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2).
Jiao X; Zhao L; Ma M; Bai X; He M; Yan Y; Wang Y; Chen Q; Zhao X; Zhou M; Cui Z; Zheng Z; Wang E; Wei M
Breast Cancer Res Treat; 2013 Jun; 139(3):717-30. PubMed ID: 23780685
[TBL] [Abstract][Full Text] [Related]
5. MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2).
Ma MT; He M; Wang Y; Jiao XY; Zhao L; Bai XF; Yu ZJ; Wu HZ; Sun ML; Song ZG; Wei MJ
Cancer Lett; 2013 Oct; 339(1):107-15. PubMed ID: 23879965
[TBL] [Abstract][Full Text] [Related]
6. miR-145 sensitizes breast cancer to doxorubicin by targeting multidrug resistance-associated protein-1.
Gao M; Miao L; Liu M; Li C; Yu C; Yan H; Yin Y; Wang Y; Qi X; Ren J
Oncotarget; 2016 Sep; 7(37):59714-59726. PubMed ID: 27487127
[TBL] [Abstract][Full Text] [Related]
7. Regulation of miR-19 to breast cancer chemoresistance through targeting PTEN.
Liang Z; Li Y; Huang K; Wagar N; Shim H
Pharm Res; 2011 Dec; 28(12):3091-100. PubMed ID: 21853360
[TBL] [Abstract][Full Text] [Related]
8. Involvement of miR-133a and miR-326 in ADM resistance of HepG2 through modulating expression of ABCC1.
Ma J; Wang T; Guo R; Yang X; Yin J; Yu J; Xiang Q; Pan X; Tang H; Lei X
J Drug Target; 2015; 23(6):519-24. PubMed ID: 25714665
[TBL] [Abstract][Full Text] [Related]
9. Decreased drug accumulation without increased drug efflux in a novel MRP-overexpressing multidrug-resistant cell line.
Gaj CL; Anyanwutaku I; Chang YH; Cheng YC
Biochem Pharmacol; 1998 Apr; 55(8):1199-211. PubMed ID: 9719474
[TBL] [Abstract][Full Text] [Related]
10. Vielanin P enhances the cytotoxicity of doxorubicin via the inhibition of PI3K/Nrf2-stimulated MRP1 expression in MCF-7 and K562 DOX-resistant cell lines.
Gao HL; Xia YZ; Zhang YL; Yang L; Kong LY
Phytomedicine; 2019 May; 58():152885. PubMed ID: 31009836
[TBL] [Abstract][Full Text] [Related]
11. MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells.
Zhong S; Li W; Chen Z; Xu J; Zhao J
Gene; 2013 Nov; 531(1):8-14. PubMed ID: 23994196
[TBL] [Abstract][Full Text] [Related]
12. miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.
Hu Y; Xu K; Yagüe E
Breast Cancer Res Treat; 2015 Jun; 151(2):269-80. PubMed ID: 25900794
[TBL] [Abstract][Full Text] [Related]
13. Salinomycin enhances doxorubicin-induced cytotoxicity in multidrug resistant MCF-7/MDR human breast cancer cells via decreased efflux of doxorubicin.
Kim KY; Kim SH; Yu SN; Park SK; Choi HD; Yu HS; Ji JH; Seo YK; Ahn SC
Mol Med Rep; 2015 Aug; 12(2):1898-904. PubMed ID: 25892525
[TBL] [Abstract][Full Text] [Related]
14. Resistance to mitoxantrone in multidrug-resistant MCF7 breast cancer cells: evaluation of mitoxantrone transport and the role of multidrug resistance protein family proteins.
Diah SK; Smitherman PK; Aldridge J; Volk EL; Schneider E; Townsend AJ; Morrow CS
Cancer Res; 2001 Jul; 61(14):5461-7. PubMed ID: 11454692
[TBL] [Abstract][Full Text] [Related]
15. Effect of β-elemene on the kinetics of intracellular transport of d-luciferin potassium salt (ABC substrate) in doxorubicin-resistant breast cancer cells and the associated molecular mechanism.
Tang CY; Zhu LX; Yu JD; Chen Z; Gu MC; Mu CF; Liu Q; Xiong Y
Eur J Pharm Sci; 2018 Jul; 120():20-29. PubMed ID: 29704644
[TBL] [Abstract][Full Text] [Related]
16. Resistance to topoisomerase II inhibitors in human glioma cell lines overexpressing multidrug resistant associated protein (MRP) 2.
Matsumoto Y; Tamiya T; Nagao S
J Med Invest; 2005 Feb; 52(1-2):41-8. PubMed ID: 15751272
[TBL] [Abstract][Full Text] [Related]
17. miR-302a/b/c/d cooperatively inhibit BCRP expression to increase drug sensitivity in breast cancer cells.
Wang Y; Zhao L; Xiao Q; Jiang L; He M; Bai X; Ma M; Jiao X; Wei M
Gynecol Oncol; 2016 Jun; 141(3):592-601. PubMed ID: 26644266
[TBL] [Abstract][Full Text] [Related]
18. 99mTc-sestamibi to monitor treatment with antisense oligodeoxynucleotide complementary to MRP mRNA in human breast cancer cells.
Kinuya S; Bai J; Shiba K; Yokoyama K; Mori H; Fukuoka M; Watanabe N; Shuke N; Michigishi T; Tonami N
Ann Nucl Med; 2006 Jan; 20(1):29-34. PubMed ID: 16485571
[TBL] [Abstract][Full Text] [Related]
19. Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin.
Pogribny IP; Filkowski JN; Tryndyak VP; Golubov A; Shpyleva SI; Kovalchuk O
Int J Cancer; 2010 Oct; 127(8):1785-94. PubMed ID: 20099276
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis.
Guo L; Liu Y; Bai Y; Sun Y; Xiao F; Guo Y
Eur J Cancer; 2010 Jun; 46(9):1692-702. PubMed ID: 20371173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
